TITLE

Factor analysis of metabolic syndrome using direct measurement of insulin resistance in Chinese with different degrees of glucose tolerance

AUTHOR(S)
Chung-Ze Wu; Jiunn-Diann Lin; Jer-Chuan Li; Fone-Ching Hsiao; Chang-Hsun Hsieh; Shi-Wen Kuo; Yi-Jen Hung; Chieh-Hua Lu; Chih-Tuseng He; Dee Pei
PUB. DATE
April 2008
SOURCE
Indian Journal of Medical Research;Apr2008, Vol. 127 Issue 4, p336
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background & objectives: With the increasing prevalence of type 2 diabetes and cardiovascular disease in Taiwan, the understanding of metabolic syndrome (MetS) becomes more important. The purpose of this study was to investigate the clustering patterns of the risk variables of the MetS with factor analysis (FacAn). Methods: A total of 564 Chinese individuals with normal glucose tolerance (N, n=345), impaired glucose tolerance (IGT, n=164) or diabetes mellitus (DM, n=55) were enrolled. Insulin resistance was measured by insulin suppression test (IST). The components of MetS such as waist hip ratio (WHR), fasting plasma glucose (FPG), systolic blood pressure (SBP), diastolic blood pressure (DBP), triglyceride (TG), high density lipoprotein cholesterol (HDLC) and steady state plasma glucose (SSPG) from IST were put into the model of exploratory FacAn. Results: In spite of the minor different loading patterns, three dimensions were identified in the three subgroups; a "blood pressure" dimension, loading with mainly SBP and DBP, an "insulin resistance" dimension, loading mainly with SSPG, and an "adiposity/glucose" dimension loading with TG, WHR or FPG. Interpretation & conclusions: Our results were consistent with different ethnic groups in earlier reports that more than two dimensions were identified and that the MetS is not unified by a single underlying aetiology, i.e., insulin resistance. Longitudinal analysis in this and other populations will be required to validate our findings and to test their generalisability.
ACCESSION #
33932641

 

Related Articles

  • Utility of Serum Inflammatory Chemokines as Markers of Metabolic Syndrome and Type II Diabetes Mellitus. Saleh, Doaa N.; Eman M. Saleh; Shaheen, Karim Y.; Shalaby, Kamal A. // Australian Journal of Basic & Applied Sciences;Jul2012, Vol. 6 Issue 7, p144 

    Background: Inflammation has repeatedly been demonstrated to be associated with themetabolic syndrome (MS) and type II diabetes mellitus (type II DM), but the relative importance ofdifferent aspects of inflammatory process is largely unexplored. Subjects: Circulating adipokine(chemerin) and...

  • Pre-diabetes and the metabolic syndrome. Gounden, Verena // CME: Continuing Medical Education;Jul2012, Vol. 30 Issue 7, p252 

    The article presents information on pre-diabetes and metabolic syndrome (MetS). Pre-diabetes is defined by the American Diabetes Association as a fasting plasma glucose and represents individuals who are at great risk of developing type 2 diabetes that can lead to cardiovascular risk. MetS is a...

  • Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes. Younghyup Lim; Soyeon Yoo; Sang Ah Lee; Sang Ouk Chin; Dahee Heo; Jae Cheol Moon; Shinhang Moon; Kiyoung Boo; Seong Taeg Kim; Hye Mi Seo; Hyeyoung Jwa; Gwanpyo Koh // Endocrinology & Metabolism;2015, Vol. 30 Issue 2, p208 

    Background: Increased low density lipoprotein cholesterol (LDL-C) level and the presence of metabolic syndrome (MetS) are important risk factors for cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM). Recent studies demonstrated apolipoprotein B (apoB), a protein mainly located in...

  • Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. Wong, S. P. Y.; Huda, M.; English, P.; Bargiotta, A.; Wilding, J. P. H.; Johnson, A.; R. Corrall; Pinkney, J. H. // Diabetologia;Dec2005, Vol. 48 Issue 12, p2641 

    Aims/hypothesis: Familial partial lipodystrophy (FPLD) and obesity are both associated with increased risks of type 2 diabetes and cardiovascular disease. Although adipokines have been implicated, few data exist in subjects with FPLD; therefore we investigated a family with FPLD due to a lamin...

  • METABOLIC SYNDROME IN CLINICAL PRACTICE: CONSIDERATIONS ON DIAGNOSTIC CRITERIA AND PREVALENCE. Vasilescu, R. // Therapeutics, Pharmacology & Clinical Toxicology;2011, Vol. 15 Issue 2, p93 

    The metabolic syndrome is defined as an association of risk factors of metabolic origin, combined with a heightened risk for cardiovascular diseases and for type 2 diabetes mellitus. The pathogenesis of the metabolic syndrome is multifactorial, the main risk factors being: obesity (abdominal...

  • Impact of Insulin Resistance on Risk of Type 2 Diabetes and Cardiovascular Disease in People With Metabolic Syndrome. Meigs, James B.; Rutter, Martin K.; Sullivan, Lisa M.; Fox, Caroline S.; D'Agostino Sr., Ralph B.; Wilson, Peter W. F. // Diabetes Care;May2007, Vol. 30 Issue 5, p1219 

    OBJECTIVE -- Metabolic syndrome increases the risk for type 2 diabetes and cardiovascular disease (CVD) and may be associated with insulin resistance. RESEARCH DESIGN AND METHODS -- We tested the hypothesis that the metabolic syndrome confers risk with or without concomitant insulin resistance...

  • Evaluation of metabolic syndrome in adults of Talca city, Chile. Mujica, Veronica; Leiva, Elba; Icaza, Gloria; Diaz, Nora; Arredondo, Miguel; Moore-Carrasco, Rodrigo; Orrego, Roxana; Vásquez, Marcela; Palomo, Ivan // Nutrition Journal;2008, Vol. 7, Special section p1 

    Objective-: Insulin resistance (IR) is an important risk factor for type 2 Diabetes Mellitus (DM2) and cardiovascular disease (CVD). Metabolic Syndrome (MS) is a clustering of metabolic alterations associated to IR; however, there is no international consensus for defining its diagnosis. Our...

  • Clinical utility of metabolic syndrome severity scores: considerations for practitioners. DeBoer, Mark D.; Gurka, Matthew J. // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;Feb2017, Vol. 10, p65 

    The metabolic syndrome (MetS) is marked by abnormalities in central obesity, high blood pressure, high triglycerides, low high-density lipoprotein-cholesterol, and high fasting glucose and appears to be produced by underlying processes of inflammation, oxidative stress, and adipocyte...

  • Does the Metabolic Syndrome Exist? Grundy, Scott M. // Diabetes Care;Jul2006, Vol. 29 Issue 7, p1689 

    The article examines whether the well-established clustering of metabolic risk factors underlying both cardiovascular disease and type 2 diabetes deserve to be called a syndrome and, even if the metabolic syndrome can be accepted as a concept, whether the concept has matured enough to be...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics